Amyloid-targeting therapies represent a significant leap forward in the fight against neurodegeneration. However, the long-term clinical efficacy of these drugs depends on their ability to arrest downstream pathologic changes. Consequently, researchers continue to study the cellular impact of amyloid clearance on tau accumulation and brain atrophy.
Analyzing Amyloid Clearance in a Unique Patient Case
In a recent study, researchers presented a fascinating case of a male in his 50s. This patient carried the p.R47H TREM2 variant, which significantly increases the risk of Alzheimer disease. Specifically, he received 30 doses of aducanumab over a span of 4.5 years. Unfortunately, the patient passed away four years after his final dose. Consequently, neuropathologists performed a detailed postmortem analysis to examine his brain pathology. In addition, they compared his tissue with fourteen untreated, matched controls.
Key Findings on Plaque Removal and Brain Anatomy
The postmortem examination revealed a highly variable pattern of plaque removal. Indeed, some brain regions showed extensive clearance of amyloid pathology, while adjacent areas retained high plaque levels. Interestingly, the patient had minimal amyloid in the superficial cortical layers but high levels in deep layers. Furthermore, researchers observed that the cleared plaques were preferentially located in the gyral crests. Therefore, anatomical location appears to play a critical role in how antibodies clear these toxic aggregates.
Slowing Tau Pathology and Atrophy
Most importantly, areas with extensive plaque removal showed a clear clinical benefit. For instance, these brain regions suffered less downstream tau pathology at autopsy. Additionally, longitudinal magnetic resonance imaging showed slower atrophy in these cleared cortical zones. This finding suggests that sufficient plaque removal can actively halt the neurodegenerative cascade. Thus, clinicians must aim for thorough plaque clearance to achieve the best therapeutic outcomes.
Frequently Asked Questions
Q1: Why is amyloid clearance unevenly distributed in the brain after therapy?
Research suggests that antibodies may clear plaques more easily from superficial cortical layers and gyral crests. Conversely, deep cortical layers and sulci seem to retain plaques longer, possibly due to regional differences in vascularity or lymphatic drainage.
Q2: Does clearing amyloid plaques actually stop Alzheimer’s disease from progressing?
Yes, the study demonstrates that areas with extensive plaque removal experience significantly less tau accumulation. Furthermore, these cleared regions show a slower rate of cortical atrophy on longitudinal brain scans.
References
- Brown CA et al. Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease. JAMA. 2026 Jul 12. doi: 10.1001/jama.2026.13058. PMID: 42437499.
- Huisman MV et al. YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer. JAMA. 2026 Jul 11. doi: 10.1001/jama.2026.10676.
- Glymphatic and meningeal lymphatic dysfunction in Alzheimer’s disease: Mechanisms and therapeutic perspectives. PMC. 2025 Oct 28.